Nanomerics Presenting at Epitarget Annual Meeting

Nanomerics' CEO Andreas Schatzlein is presenting new data on the use of the MET platform for the potential treatement of epilepsy at the Epitarget annual meeting in Warsaw (11-13 Oct). Epitarget  ( is a large European research consortium funded by the EU under the FP7 framework. Nanomerics has joined this consortium to support the CNS delivery of  novel therapeutics developed by the consortium partners.

Share this post